Cargando…
Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934043/ https://www.ncbi.nlm.nih.gov/pubmed/27390610 http://dx.doi.org/10.7150/jca.15213 |
_version_ | 1782441273485950976 |
---|---|
author | Hsieh, Meng-Che Huang, Cheng-Hua Chiang, Po-Hui Chen, Yen-Yang Tang, Yeh Su, Yu-Li |
author_facet | Hsieh, Meng-Che Huang, Cheng-Hua Chiang, Po-Hui Chen, Yen-Yang Tang, Yeh Su, Yu-Li |
author_sort | Hsieh, Meng-Che |
collection | PubMed |
description | Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patients who were initially diagnosed to have mUCB and received MVAC or GC as metastatic first-line chemotherapy between 2000 and 2014 at Kaohsiung Chang Gung Memorial Hospital were reviewed. Totally, 130 patients were enrolled into our study. Univariable Cox proportional hazard models were constructed for OS. Hazard ratio (HR) and 95% confidence intervals (CIs) was also presented. Results: There were 50 patients (38%) in the MVAC group and 80 patients (62%) in the GC group. The median OS was insignificantly different between MVAC and GC groups, accounting for 17.0 and 14.4 months (P = 0.214), respectively. OS of MVAC group was significantly longer with regard to age ≦ 60 years (HR: 0.38, 95% CI: 0.12-0.97, P = 0.036), pure urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015), > 1 metastatic sites (HR: 0.19, 95% CI: 0.08-0.44, P = < 0.001), and neutrophil to lymphocyte ratio > 3(HR: 0.45, 95% CI: 0.25-0.81, P = 0.006), while OS with GC group was significantly longer with regard to variant urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015). Conclusions: Our study disclosed the predictive factors of different regimen for mUCB. These results have clinical implication for physicians who treat patients with mUCB. |
format | Online Article Text |
id | pubmed-4934043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-49340432016-07-07 Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder Hsieh, Meng-Che Huang, Cheng-Hua Chiang, Po-Hui Chen, Yen-Yang Tang, Yeh Su, Yu-Li J Cancer Research Paper Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patients who were initially diagnosed to have mUCB and received MVAC or GC as metastatic first-line chemotherapy between 2000 and 2014 at Kaohsiung Chang Gung Memorial Hospital were reviewed. Totally, 130 patients were enrolled into our study. Univariable Cox proportional hazard models were constructed for OS. Hazard ratio (HR) and 95% confidence intervals (CIs) was also presented. Results: There were 50 patients (38%) in the MVAC group and 80 patients (62%) in the GC group. The median OS was insignificantly different between MVAC and GC groups, accounting for 17.0 and 14.4 months (P = 0.214), respectively. OS of MVAC group was significantly longer with regard to age ≦ 60 years (HR: 0.38, 95% CI: 0.12-0.97, P = 0.036), pure urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015), > 1 metastatic sites (HR: 0.19, 95% CI: 0.08-0.44, P = < 0.001), and neutrophil to lymphocyte ratio > 3(HR: 0.45, 95% CI: 0.25-0.81, P = 0.006), while OS with GC group was significantly longer with regard to variant urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015). Conclusions: Our study disclosed the predictive factors of different regimen for mUCB. These results have clinical implication for physicians who treat patients with mUCB. Ivyspring International Publisher 2016-06-27 /pmc/articles/PMC4934043/ /pubmed/27390610 http://dx.doi.org/10.7150/jca.15213 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Hsieh, Meng-Che Huang, Cheng-Hua Chiang, Po-Hui Chen, Yen-Yang Tang, Yeh Su, Yu-Li Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title | Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title_full | Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title_fullStr | Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title_full_unstemmed | Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title_short | Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder |
title_sort | tailored selection of first-line cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma of bladder |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934043/ https://www.ncbi.nlm.nih.gov/pubmed/27390610 http://dx.doi.org/10.7150/jca.15213 |
work_keys_str_mv | AT hsiehmengche tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder AT huangchenghua tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder AT chiangpohui tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder AT chenyenyang tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder AT tangyeh tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder AT suyuli tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder |